SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
Information source: Desitin Arzneimittel GmbH
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parkinson's Disease
Intervention: Piribedil (Drug)
Phase: N/A
Status: Completed
Sponsored by: Desitin Arzneimittel GmbH
Summary
The aim of the non-interventional Post Marketing Study is to investigate the use of the
non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy
in patients with Morbus Parkinson. Tolerability and course of the disease or change of
parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists
will be documented under routine conditions. Piribedil should be prescribed according to its
marketing authorisation by the responsible neurologist.
Clinical Details
Official title: Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.
Study design: Time Perspective: Prospective
Primary outcome: to monitor use in real practice including adverse events on piribedil
Secondary outcome: Efficacy
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male and female patients 18 years and older.
- Indication: Morbus Parkinson.
- Treatment with piribedil for the first time.
- Monotherapy with piribedil.
- Combination therapy with L-Dopa (from the beginning or secondary) and/or in
combination with other antiparkinsonian drugs.
Exclusion Criteria:
Locations and Contacts
Additional Information
Related publications: Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006 Apr;21(4):500-9. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006 Dec;21(12):2110-5. Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord. 2004 Dec;19(12):1524-5.
Starting date: January 2008
Last updated: March 30, 2010
|